Ginkgo Bioworks Holdings Inc vs Moody's Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.58 (market cap $505.73M), while Moody's Corporation trades at $477 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 163.2× Ginkgo Bioworks Holdings Inc's market cap, and Moody's Corporation pays a 0.86% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MCO | |
|---|---|---|
Market Cap | $505.73M | $82.52B |
Sector | Health | Financials |
52-Week High | $16.14 | $539.61 |
52-Week Low | $5.48 | $412.23 |
Enterprise Value | $607.68M | $88.54B |
Dividend Yield | — | 0.86% |
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →